Ono Pharmaceutical and Shattuck Labs Collaborate to Develop Bifunctional Fusion Proteins for Treating Autoimmune and Inflammatory Diseases
Shots:
- Ono Pharmaceutical and Shattuck Labs have signed a drug discovery collaboration and option agreement to develop bifunctional fusion proteins for pathways of autoimmune and inflammatory diseases
- As per the agreement, Shattuck will utilize its protein engineering technology to produce fusion proteins that will be provided to Ono for additional optimization and clinical development
- Furthermore, Shattuck will receive a total of $227M which includes upfront payment, milestones based on R&D and commercialization as well as research funding along with tiered sales-based royalties. Ono secures exclusive option rights to develop and commercialize potential drug candidates globally resulting from the partnership
Ref: Ono Pharmaceutical | Image: Ono Pharmaceutical
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
